Today's Hours: 8:00am - 10:00pm
Lane Medical Library

Search

Filter Results

Did You Mean:

Search Results

Sort by
relevance
  • Book
    Editors, Jeanne E. Poole, Lyle W. Larson.
    Contents:
    The hardware of ICD and pacemaker pulse generators and leads / Brian Olshansky
    Surgical anatomy / Corinne Fligner and Lyle W. Larson
    Surgical tools and techniques / Otway Louie and Lyle W. Larson
    Anesthesia for interventional cardiology / Stefan Lombaard, Joanna M. Davies, and Alec Rooke
    Radiation safety / Melissa Robinson
    Patient preparation / Christine Cramer-Mitchell and Lyle W. Larson
    The surgical procedure / Jeanne E. Poole
    Transvenous lead placement / Andrea M. Russo and Ulrika Birgersdotter-Green
    Considerations for novel or alternative lead placement / Nazem Akoum and Joshua Hermsen
    Implanting the subcutaneous implantable cardioverter-defibrillator
    Kristen K. Patton
    Challenges in the pediatric and young adult patients requiring a cardiac rhythm device / Frank Cecchin
    Special circumstances and obstacles / Roger Carrillo and Chris Healy
    Pitfalls and complications / Marye Gleva and Charles Huddleston
    Prevention, evaluation, and management of cardiac rhythm device infections / Jordan M. Prutkin and Paul Pottinger
    Post-operative management / Linda Mariott and Lyle W. Larson.
    Digital Access ScienceDirect 2018
  • Article
    Tornyos K, Silberman H, Solomon A.
    Cancer Treat Rep. 1977 Aug;61(5):785-7.
    Thirteen patients with multiple myeloma (MM) who either failed to respond to or who were relapsing from standard agents and who received four or more courses of methyl-CCNU + prednisone (adequate drug trial) are reported in this paper. Methyl-CCNU was given orally before breakfast at 6-week intervals at a starting dose of 50 mg/m2 with the intention of increasing the dose to 100, 150, and 200 mg/m2 with each subsequent course. The dose of prednisone was 75 mg/day x 7 with each course. The response rate was 46% (six of 13 patients). No patient had better than a fair response. Drug toxicity, severe enough to prevent further dose escalation, was observed in every case. Prior BCNU therapy or the lack of response to previous alkylating agents did not prevent a response to methyl-CCNU + prednisone. The response rate of methyl-CCNU + prednisone in MM is comparable to the results achieved with other agents in similar groups of patients.
    Digital Access Access Options